Kornimate/medical-research-clean huggingface dataset:
a cohort of patients with chronic pulmonary disease

Conditions: Obstructive Pulmonary Disease

Summary: this is a longitudinal study of following chronic pulmonary disease patients to observe and predict the clinical outcomes of these patients.

in patients with chronic pulmonary disease, impaired pulmonary function and limited exercise capacity, is a complex clinical syndrome with a wide range of underlying causes, which may result in worse quality of life and high economic burden. this is a longitudinal study of following chronic pulmonary disease patients, recording the clinical, pathophysiology, and psychological parameters, to observe and predict the clinical outcomes of these patients.

Eligibility criteria:
inclusion criteria: 1. age 18-80, males and females 2. patients are diagnosed as the obstructive pulmonary disease according to the clinical practice. 3. willing to participate in the study. 4. being able to provide informed consent. exclusion criteria: 1. subjects with severe heart failure, severe arrhythmias, unstable angina, and malignant comorbidities. 2. subjects with significantly impaired cognitive function and are unable to fulfill the study requirement (unable to provide informed consent) 3. subjects who participated in another trial within 30 days prior to the planned start of the study 4. subjects with cancer or have had cancer in the 5 years prior to study entry.
efficacy of voluven® for the prevention of hypotension during spinal anesthesia for cesarean section

Conditions: Hypotension

Summary: the aim of the study is to evaluate the efficacy of voluven® in the prevention of maternal hypotension in women undergoing spinal anesthesia for cesarean section

intravenous fluid administration prior to spinal anesthesia for cesarean section is an established part of anesthetic practice for the prevention of maternal hypotension. systematic reviews of clinical data suggest the usefulness of administering colloids to decrease the incidence of hypotension this study will compare the clinical efficacy and safety of hes 130/0.4 (6%) in normal saline vs. ringer's lactate solution in prevention of hypotension during spinal anesthesia for elective cesarean section.

Eligibility criteria:
inclusion criteria: * elective cesarean section applying spinal anesthesia * ≥ week 37 of gestation * singleton pregnancy exclusion criteria: * suspicion of any hypertensive disease * parturient in labor

Keywords: cesarean section spinal anesthesia hypotension
safety of imovax polio in chinese infants and children

Conditions: Poliomyelitis

Summary: to describe the tolerance in terms of occurrence of serious adverse reactions and severe adverse reactions (injection site and systemic) within eight days after one dose of imovax polio™ administered in children and infants.


Eligibility criteria:
inclusion criteria: * group 1: aged 18 months (18-20 months) on the day of inclusion * group 2: aged 2 months (56-70 days) on the day of inclusion exclusion criteria: * participation in another clinical trial in the 4 weeks preceding the trial vaccination * planned participation in another clinical trial during the present trial period * congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy * systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances * chronic illness at a stage that could interfere with trial conduct or completion * blood or blood-derived products received in the past 3 months (for group 1) or since birth (for group 2) * any vaccination in the 4 weeks preceding the trial vaccination (except bcg and hepatitis b \[hep b\] for group 2) * vaccination planned in the 4 weeks following the trial vaccination * group 1: previous booster vaccination against the poliomyelitis infection with the trial vaccine or with another vaccine. * group 2: previous vaccination against the poliomyelitis infection with the trial vaccine or with another vaccine. * history of poliomyelitis infection (confirmed either clinically, serologically or microbiologically) * clinical or serological evidence of systemic illness including hepatitis b, c and hiv * thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination * history of/current seizures * febrile illness (axillary temperature ≥ 37.4°c) or acute illness on the day of inclusion

Keywords: imovax; poliomyelitis
tomotherapy for leptomeningeal metastases

Conditions: Leptomeningeal Metastasis

Summary: this clinical trial was designed to investigate the efficiency and toxicity of tomotherapy for leptomeningeal metastases.

this is a single-arm, single center, phase ii trial to investigate the feasibility and toxicity of tomotherapy for leptomeningeal metastases, which are defined as leptomeningeal metastases with or without brain metatstases.

Eligibility criteria:
inclusion criteria: * histologic or cytologic diagnosis of primary tumor and conformed meningeal metastases by enhanced mri; kps ≥60,or kps ≥40 and the limitation of motion is simply caused by brain tumor that is adjacent to the motor function areas; age: 18-75 years old; adequate organ function:wbc≥4.0x109/l neu ≥ 1.5x109/l hemoglobin ≥ 110 g/l platelets ≥100 x109/l total bilirubin ≤ 1.5x uln ast and alt ≤ 1.5x uln bun and cr: within the normal range. exclusion criteria: * other clinically significant diseases (e.g.myocardial infarction within the past 6 months, severe arrhythmia); unable or unwilling to comply with the study protocol; patients who are anticipated in other clinical trials of meningeal metastases; pregnant patients or female patients whose hcg is positive; unsuitable to participate in study, that in the opinion of the treating physician.

Keywords: tomotherapy leptomeningeal metastases fractionated stereotactic radiotherapy
efficacy of two nasal products based on diluted seawater in the treatment of upper respiratory infections/conditions

Conditions: Rhinitis; Sinusitis; Upper Respiratory Infections; Colds

Summary: the goal of this interventional clinical trial is to test the safety and efficacy of two medical devices in subjects aged from 3 months old for the treatment of colds, rhinitis, sinusitis, and other upper respiratory infections/conditions for 7 days.

the main endpoint is a symptom score evaluation. severity is evaluated using the jackson scale, which includes 8 symptoms (nasal discharge, nasal congestion, sneezing, sore throat, cough, headache, discomfort, chills) rated as absent, mild, moderate, or severe by the physician/investigator, on day 0, immediately after the first use, on day 3, and on day 7. the clinical evaluation is also conducted by the ent specialist using the cgi (clinical global impression - 7-point scale) on day 0, immediately after the first use, on day 3, and on day 7, and by patients using the pgi (patient global impression - 7-point scale) every day. concomitant treatments, number and timing of daily use, and tolerance (adverse effects) will also be studied.

Eligibility criteria:
inclusion criteria: * autonomous adult, or minor with the consent of their legal representative * adults and children from 3 months old * ability of the patient (for adults) or their legal representative (for children) to follow the instructions for product use * having signed a free and informed consent to participate in the study expressed by the patient (for adults) or by their legal representative (for children) after being informed by the doctor. * person with an upper respiratory tract infection (cold, rhinitis, rhinopharyngitis...) with symptoms of nasal congestion and nasal discharge of moderate to severe intensity (jackson derived score (nasal congestion + nasal discharge) ≥ 4 on day 0). * persons with symptoms that started no more than 48 hours before the first visit exclusion criteria: * person not showing cold symptoms, particularly no nasal congestion (chronic dry rhinitis, or jackson derived score (nasal congestion + nasal discharge) \&lt; 4 on day 0). * person undergoing treatment with a cortisone derivative, mucolytic, or medication containing pseudoephedrine or a similar product acting on nasal congestion or having used such a product within the 3 days preceding inclusion. * person having used a nasal wash product within the 3 days preceding inclusion. * person whose ability to use the product daily and complete the daily follow-up diary is in doubt. * person refusing to sign the informed consent form prior to the study. * person participating or having participated in any other clinical study within the 30 days preceding the study. * person participating in any other clinical study.
global sinus surgery registry

Conditions: Chronic Rhinosinusitis; Recurrent Acute Rhinosinusitis

Summary: this study evaluates long-term safety and effectiveness of primary sinus surgery in a real-world population of adults with chronic rhinosinusitis (crs) or recurrent acute rhinosinusitis (rars). this post-market study will evaluate sinus surgery performed using commercially available sinus instrumentation (e.g. sinus balloon catheters, powered microdebriders, manual instruments).


Eligibility criteria:
inclusion criteria: * age ≥ 18 years or minimum adult age as required by local regulations * the subject has a planned primary sinus surgery, which includes either traditional transnasal endoscopic sinus surgery (ess), balloon sinus dilation (bsd) or a hybrid procedure * subjects diagnosed by ent surgeon with chronic rhinosinusitis (crs) or recurrent acute rhinosinusitis (rars) per aao-hns or epos adult sinusitis clinical practice guidelines * the subject has been informed of the nature of the registry and has consented to participate and authorized the collection and release of medical information by signing a consent form * subject is able to read and understand local language exclusion criteria: * prior sinus surgery. septoplasty, nasal polypectomy, septorhinoplasty, nasal valve and turbinate reduction surgeries are not exclusions * planned surgery of any of the following : orbital decompression, skull base, neoplasm, lacrimal, uppp, aesthetic surgery, potts puffy tumor, draf iii * planned external approaches (i.e. not trans-nasal) * planned off-label usage of balloon sinus dilation products. * balloon sinus dilation performed with a non-acclarent balloon product
study of effects of sutures on results of palate surgery for obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: in this study we will examine whether suture repair of the palate, or roof of mouth, has any effect on results of palate surgery performed for treatment of obstructive sleep apnea.

uvulopalatopharyngoplasty, or uppp, is the most common surgical procedure performed for the treatment of obstructive sleep apnea. the procedure involves removal of redundant tissue from the lower palate (roof of mouth), including the uvula, and then suturing the cut edges of the remaining tissue together. however it is frequently noted by surgeons that sutures placed in the roof of the mouth do not stay intact. also, in standard tonsillectomy, which involves removal of the tonsils and thus creation of a wound near the palate, no suturing is used, which does not seem to affect how the area heals. previous studies have shown no significant differences in complication rates, post-operative pain, or symptom outcomes in patients undergoing tonsillectomy either with or without suture repair of the tonsillectomy wound. in this study we will examine whether suture repair following uppp has any effect on post-operative pain, healing, or treatment success in terms of symptom resolution or post-operative sleep study results.

Eligibility criteria:
inclusion criteria: * sleep-study documented obstructive sleep apnea * sleep apnea refractory to non-surgical treatments including continuous positive airway pressure (cpap) * age \> 21 exclusion criteria: * previous palate surgery

Keywords: obstructive sleep apnea airway obstruction sleep-disordered breathing
pilates exercise and inhalation injury post burn

Conditions: Inhalation Injury

Summary: sixty patients with 25-45 years of age presenting post burn inhalation injury, randomly distributed into two equal groups, 30 patients for each group. control group receive conventional chest physiotherapy (diaphragmatic respiratory exercises, apical breathing exercises) for (15-20) minutes 3times/week and medical treatment for 4 weeks as a total period of treatment. study group will receive pilates exercise in addition to their conventional chest physiotherapy for (15-20) minutes 3times/week and medical treatment for 4 weeks as a total period of treatment, computerized spirometer assessment before treatment are ( the following variables were measured: forced vital capacity (pvc%) and forced ·expiratory volume in one second (fevl %) and peak expiratory flow (pef %)and after one month

two groups of sixty patients (thirty patients in each group) of both sexes of inhalation injury post burn are selected randomly to participate in the study. the patients will be divided into two equal groups in number: * group (a) study group: this group includes 30 patients who have postburn inhalation injury will receive conventional chest physiotherapy (diaphragmatic respiratory exercises, deep inhalation exercises, and respiratory exercises associated with shoulder flexion movements and extension of the upper limbs, assisted cough, circulatory exercises and early ambulation) and medical treatment and pilates method. * group (b) control group: this group includes 30 patients who have postburn inhalation injury will receive conventional chest physiotherapy (diaphragmatic respiratory exercises, deep inhalation exercises, and respiratory exercises associated with shoulder flexion movements and extension of the upper limbs, assisted cough, circulatory exercises and early ambulation) and medical treatment. * computerized spirometer assessment before treatment are ( the following variables were measured: forced vital capacity (pvc%) and forced ·expiratory volume in one second (fevl %) and peak expiratory flow (pef %)and after one month

Eligibility criteria:
inclusion criteria: * age ranged between 25-45 years. * all patients presented post-burn inhalation injury. * patients with facial burn or upper limb burn. * all patients would be free of acute or chronic pulmonary disease and will have the capacity to perform the protocol evaluation tests properly. * all patients enrolled to the study would have their informed consent. exclusion criteria: * cardiac diseases. * chronic pulmonary disorders. * previous or present smoking history. * female patients who are pregnant and lactating. * post-burn patient on icu.

Keywords: pilates exercise ,lung functions ,inhalation injury
clinical validation of the alivecor kardia 12l and 6l devices

Conditions: Arrhythmia

Summary: alivecor (www.alivecor.com) has developed an ecg device (kardiamobile) that interfaces with ios and android smartphones and tablets. this ecg consists of a lightweight hardware case with two metal electrodes that can snap onto the back of the phone and a software application. by holding the right finger(s) on the right electrode and the left finger(s) on the left electrode, an electrical circuit is completed and a lead-i, 30 second rhythm strip is created. kardiamobile and a newer device, kardiamobile 6l, were approved by fda for ecg rhythm recording. recently, alivecor developed two new devices: kardia 12l and kardia 6l to record 12- lead and 6-lead ecgs, respectively. however, the data generated from the two new devices have not yet been validated for accuracy. the purpose of this study is to evaluate the accuracy of the ecgs recorded by alivecor kardia 12l and 6l devices. this will be compared to simultaneous standard of-care 12-lead ecg recordings. the ecgs will be analyzed for accuracy and statistical difference using root-mean-square error and cross correlation between the median beats.


Eligibility criteria:
inclusion criteria: 1. male and female patients 18 years old or older 2. ability to sit for an ecg and alivecor kardia 12l and kardia 6l recordings for 20 minutes exclusion criteria: 1. any internal stimulator that would generate electrical interference with the recording system of the alivecor kardia 12l or kardia 6l. 2. open chest wounds or recent (\<30 days) surgery to the chest or abdomen. 3. absence of any limb that would require modification of the lead set-up
outcomes of bilateral temporomandibular joint arthroscopy and the role of a second intervention - timings and results

Conditions: Bilateral Temporomandibular Joint Disorder

Summary: temporomandibular joint (tmj) arthroscopy has been used successfully for intra-articular disorders. until now, limited studies are available regarding the clinical evidence of bilateral tmj arthroscopy for dimitroulis 2-3. this prospective study investigated the efficacy of tmj arthroscopy in patients with bilateral disorders, and also the need for a posterior surgery.

temporomandibular joint (tmj) arthroscopy has been used successfully for intra-articular disorders. it was first introduced by onishi at 1975, as a pioneering technique to treat painful joints and has been associated with a reduction in the number of open joints surgeries. this minimally invasive technique allows observation of the tmj upper compartment tissues, and sometimes the lower compartment. moreover, this intervention allows joint lysis and lavage (level 1 arthroscopy) and intra-articular surgical procedures (level 2-3 arthroscopy). recent studies updated that tmj arthroscopy promotes a reduction in pain and inflammatory process and restoring the mandibular function with low morbidity. moreover, tmj arthroscopy seems to be also long-term effective for relieving tmj symptoms. until now, limited studies are available regarding the clinical evidence of bilateral tmj arthroscopy for dimitroulis 2-3. this prospective study investigated the efficacy of tmj arthroscopy in patients with bilateral disorders, and also the need for a posterior surgery.

Eligibility criteria:
inclusion criteria: * age \>16 years; * clinical diagnosis of bilateral intra-articular disorder; * clinical criteria for bilateral tmj arthroscopy; * magnetic resonance imaging (mri) assessing the intra-articular derangement exclusion criteria: * the exclusion criteria included any history of previous tmj surgical intervention or any facial trauma within the last 4 weeks prior the study. * severe medical problems or mental illness, and pregnancy were also exclusion criteria

Keywords: temporomandibular joint tmj arthroscopy tmj surgery
can her2 targeted pet/ct imaging identify unsuspected her2 positive breast cancer metastases, which are amenable to her2 targeted therapy?

Conditions: Breast Cancer Metastases; HER2 Positive Breast

Summary: some breast cancer cells make a protein called human epidermal growth factor receptor 2 (her2). patients with her2 positive (her2+) breast cancer receive medicine that attacks her2, which helps these patients live longer. some her2 negative (her2-) breast cancer patients also benefit from medicines that attack her2, but we do not know why or which patients will benefit. this study uses a new imaging method, her2-targeted pet/ct, to identify patients that may benefit from medicines that attack her2. this is experimental.


Eligibility criteria:
inclusion criteria: * women age \> 18 * biopsy proven her2 negative primary breast cancer and biopsy proven metastatic disease. * 5 or more foci of demonstrable metastases on recent imaging modalities (ct, mr, fdg pet/ct) * ecog performance score of 0-2 exclusion criteria: * life expectancy \< 3months * pregnancy or lactation * patients who cannot undergo pet/ct scanning because of weight limits * cns only disease on recent imaging

Keywords: 89zr-trastuzumab pet/ct 14-156 89zr-pertuzumab her2-targeted
cabocheck - cabozantinib in adult patients with advanced renal cell carcinoma following prior systemic check point inhibition therapy: a retrospective, non-interventional study

Conditions: Advanced Renal Cell Carcinoma (All Subtypes); Metastatic Renal Cell Carcinoma (All Subtypes)

Summary: this is a non-interventional study to retrospectively evaluate the safety and to describe the effectiveness of cabozantinib after immunoncologic treatment with nivolumab or nivolumab plus ipilimumab in routine clinical practice. it consists of a retrospective chart review of patients who have already completed treatment with cabozantinib after nivolumab or nivolumab plus ipilimumab before inclusion.


Eligibility criteria:
inclusion criteria: 1. written informed consent and any locally-required authorization (eu data privacy directive in the eu) obtained from the subject 2. patients with advanced or metastatic renal cell carcinoma, including all subtypes 3. age ≥ 18 years 4. completion of treatment with nivolumab or nivolumab / ipilimumab combination therapy (any line of therapy) directly followed by cabozantinib treatment exclusion criteria: 1. patients who are unable to consent because they do not understand the nature, significance and implications of the observational trial 2. involvement in the planning and / or conduct of the study (applies to both ipsen staff and/or staff of sponsor and study site)
ch-eus in diagnosis of inoperable bile duct tumors

Conditions: Inoperable Disease; Bile Duct Cancer

Summary: validation of the superiority of contrast enhanced endoscopy to standard endoscopy in the diagnosis of bile duct tumors


Eligibility criteria:
inclusion criteria: * bile duct tumor diagnosed at endoscopic us, ct scan or mri * inr\ 50.000 * written consent form exclusion criteria: * inr\>1.5; platelets \< 50.000 * duodenal invasion or stenosis * patients denial * previous treatment for hepato-biliary tumors
chemoradiotherapy hnscc, randomized study, docetaxel,cisplatin, 5fu,erbitux.

Conditions: Squamous Cell Head and Neck Carcinoma

Summary: the purpose of this study is to demonstrate that induction chemotherapy followed by radiation therapy plus cetuximab will give better results than the validated treatment (chemoradiotherapy), for treatment of locoregional advanced head and neck cancers.

concurrent chemoradiotherapy (radiotherapy+ carboplatin + 5fu) is a validated treatment for patients with locoregional advanced head and neck cancers. this study evaluates the outcome of induction chemotherapy (docetaxel, cisplatin, 5 fu) followed by radiation therapy + erbitux for patients with head and neck carcinoma with almost one measurable lesion by rmi or ct scan. we hope we can improve the progression free survival of 14% at two years .

Eligibility criteria:
inclusion criteria: * head and neck locally advanced,non metastatic carcinoma * not suitable for surgery exclusion criteria: * non squamous cell head and neck cancer * previous malignancy * previous treatment

Keywords: induction chemotherapy followed by irradiation and concurrent erbitux, or radiochemotherapy